Patent · US Active

PDE5 inhibitor powder formulations and methods relating thereto

US11911390B2 · kind B2 · utility

0Cited by

1References

11Claims

0Family size

Assignee

Respira Therapeutics, Inc. · US

Inventors

Zhen Xu · Ann Arbor, US
Hugh Smyth · Austin, US
Aileen Gibbons · New York, US
Revati Shreeniwas · Palo Alto, US
Pravin Soni · Union City, US
Dan Deaton · Apex, US
James B. Hannon · Somers, US
Stephen Lermer · Austin, US
Robert Curtis · Santa Fe, US
Martin Donovan · Austin, US

Key dates

Filing date	Mar 24, 2021
Grant date	Feb 27, 2024
Priority date	—
Expiry date	Apr 17, 2041

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.